Aurora Cannabis Inc. sent out a notice on June 18, 2025, refuting an article posted on the same day that claimed the company had agreed to acquire New Zealand-based Medleaf Therapeutics.
The Canadian-based cannabis company says it has “not entered into any such agreement, has had no discussions with Medleaf Therapeutics with respect to any business combination transaction, and has not made any statement or filed any information pertaining to any such transaction.”
The statement refutes an article first published on investing.com, which claimed Aurora had announced the partnership with the European pharmaceutical distributor to expand its medical cannabis presence in Germany and other EU markets.
“We can confirm information alleging business transactions are false, without any merit,” a media spokesperson confirmed in an email to StratCann.
The original article, which claims to have been written with the use of AI, states that it was based on an SEC filing (Form 6-K SEC) and includes several specific details, as well as what are apparently fabricated quotes from Aurora Cannabis CEO Miguel Martin.
Form 6-K is an SEC reporting form under which SEC-registered FPIs provide ongoing disclosure about corporate news.
Then, in a second press release on June 19, Aurora noted that later in the day on June 18, 2025, a second article was posted on Investing.com that incorrectly states that Aurora has entered into a strategic partnership with MediPharm GmbH for distribution of medical cannabis in Germany and other EU markets. Aurora denies this article as well.
Medleaf Therapeutics is a New Zealand-based medical cannabis company. Medical cannabis has been legal in New Zealand since April 1, 2020, under the country’s Medicinal Cannabis Scheme. In May 2024, Aurora Cannabis first announced the arrival of Aurora-branded medical cannabis products to New Zealand.
Earlier this year, Canadian cannabis producer Pure Sunfarms announced it had begun shipping to the New Zealand market through a supply agreement with Medleaf.
MediPharm GmbH is a German-based pharmaceutical company.
Aurora Cannabis recently reported $90.5 million in net revenue for the three months ended March 31, 2025 (Q4 2025), $27.6 million in gross profit, and a $17.2 million net loss.
The company’s net revenue was up 3% from the previous quarter and 34% year-over-year, while gross profit was down 63% from the previous quarter and 40.5% year-over-year. Net losses decreased 160.9% from the previous quarter’s net profit of $28.2 million, but were down 17.2% from the $20.8 million loss in Q4 2024.
Note: This article has been edited to include Aurora’s second press release in regard to the claims related to MediPharm GmbH.
